Consolidated sales of the Ceva Group reached EUR766 million (US$832 million) at the end of 2014, representing growth of 23 percent and an increase of 14.1 percent at a constant perimeter and exchange rates. Sales grew in all zones and across all species with particularly strong performance being recorded in companion animals. Sales in the companion animal business were up 17.3, while sales in Ceva’s poultry business were up 14 percent.
The company released its 2014 financial figures on March 4.
The animal health group delivered an operational result slightly ahead of the budgeted objective but also continued to make significant investment in research and development, where spending exceeded 9 percent of sales. The integration of Sogeval proved to be a major success, the company stated, with the creation of a new Ceva Sogeval campus in Laval, France, and significant growth in sales (up 21 percent) in France of the joint business.
Marc Prikazsky, Ceva’s chairman and CEO commented: “The consistency in our performance is particularly pleasing and stems from our innovative pipeline of products that should continue to drive growth in the years ahead. I’m delighted by the way we were able to integrate Sogeval into the group, with minimal disruption and indeed a very strong result in France.”